10x Genomics (TXG) Asset Writedowns and Impairment (2023 - 2025)

10x Genomics has reported Asset Writedowns and Impairment for 3 years, with the latest figure at $114000.0 in Q1 2025.

• Quarterly Asset Writedowns and Impairment fell 95.35% year-over-year to $114000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2026 was $114000.0 (down 84.03% YoY) and the FY2025 annual result came in at $814000.0, down 73.35% from the prior year.
• Asset Writedowns and Impairment fell to $114000.0 in Q1 2025 per TXG's latest filing, from $600000.0 in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $7.1 million in Q4 2023 and troughed at $114000.0 in Q1 2025.
• A 3-year average of $2.6 million and a median of $2.5 million in 2024 frame the typical range for Asset Writedowns and Impairment.
• The sharpest annual moves came in 2024 and 2025: Asset Writedowns and Impairment sank 91.5% in 2024, then slumped 95.35% in 2025.
• Over 3 years, Asset Writedowns and Impairment stood at $7.1 million in 2023, then tumbled by 91.5% to $600000.0 in 2024, then slumped by 81.0% to $114000.0 in 2025.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $114000.0, $600000.0, and $2.5 million for Q1 2025, Q4 2024, and Q1 2024 respectively.